MEROPENEM ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H25N3O5S
Molecular Weight	383.463
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=DMJNNHOOLUXYBV-PQTSNVLCSA-N

InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C17H25N3O5S
Molecular Weight	383.463
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.html
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |

Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 232 Target ID: CHEMBL2354204 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Skin structure infections 18 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Curative	Approved 8360	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11
Intra-abdominal infections 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Primary	Approved 8360	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11
Bacterial meningitis 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Curative	Approved 8360	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0044	http://www.3bsc.com/index/pro_info.php?id=19400
3B Scientific (Wuhan) Corp	3B1-01460	http://www.3bsc.com/index/pro_info.php?id=21672
3B Scientific (Wuhan) Corp	3B2-1156	http://www.3bsc.com/index/pro_info.php?id=54872
AEchem Scientific Corp., USA	AE1-006420	http://www.aechemsc.com/info_products/AE1-006420.php
AHH Chemical co.,ltd	API-1041	http://www.ahhchemical.com/product/API-1041.html
AHH Chemical co.,ltd	MT-53511	http://www.ahhchemical.com/product/MT-53511.html
AK Scientific, Inc. (AKSCI)	J10087	http://www.aksci.com/item_detail.php?cat=J10087
Aaron Chemicals	AR00397K	http://www.aaronchem.com/96036-03-2
Achemo Scientific Limited	AC-13275	http://www.achemo.com/search/?Keyword= 96036-03-2
Achemtek	0101-001564	http://www.achemtek.com/96036-03-2
Acorn PharmaTech	ACN-048182	http://www.acornpharmatech.com/
Adooq BioScience	A10569	https://www.adooq.com/meropenem.html
Ambeed	A647306	https://www.ambeed.com/products/96036-03-2.html
ApexBio Technology	A5124	http://www.apexbt.com/meropenem-22012.html
AstaTech, Inc.	45000	http://www.astatechinc.com/CPSResult.php?CRNO=1382
Aurum Pharmatech LLC	S-3680	http://www.Aurumpharmatech.com/Product/ProductDetails/S_3680
AvaChem Scientific	1716	http://www.avachem.com/productSearch.asp?1716
BLD Pharm	BD23263	http://www.bldpharm.com/products/96036-03-2.html
BioSynth	M-2780	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/M-2780.html
CSNpharm	CSN13108	https://www.csnpharm.com/products/meropenem.html
Capot Chemical	17275	http://www.capotchem.com/en/17275.htm
Capot Chemical	PubChem17275	http://www.capotchem.com/en/17275.htm
Chem Scene	CS-1865	http://www.chemscene.com/96036-03-2.html
ChemMol	2100052	http://www.chemmol.com/chemmol/2100052.html
ChemMol	97602823	http://www.chemmol.com/chemmol/97602823.html
Chemspace	CSSB00020615435	https://chem-space.com/CSSB00020615435
Chiralblock Biosciences	CB11530	http://www.chiralblock.com/products/96036-03-2.html
Clearsynth	CS-M-58087	http://www.clearsynth.com/en/CSM58087.html
DC Chemicals	DCAPI1395	http://www.dcchemicals.com//product_show-Meropenem.html
Glentham Life Sciences	GP7412	http://www.glentham.com/products/product/GP7412/
Hairui	HR124915	http://www.hairuichem.com/en/product/119478-56-7.html
Hairui	HR127380	http://www.hairuichem.com/en/product/96036-03-2.html
Lab Network	LN00174071	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00174071
Matrix Scientific	75811	https://www.matrixscientific.com/075811.html
MedChem Express	HY-13678	https://www.medchemexpress.com/meropenem.html
MuseChem	A000590	https://www.musechem.com/product/A000590.html
OChem	7522	http://www.ocheminc.com/index.php?act=psearch&pid=036M032
Oakwood	M05727	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130064&ExtHyperLink=1
Oakwood	36531	http://www.oakwoodchemical.com/p-31256-036531.aspx
Sinfoo Biotech	S061047	http://www.sinfoobiotech.com/product/1064450
Smolecule	S535012	http://www.smolecule.com/products/s535012
Smolecule	S795550	https://www.smolecule.com/products/s795550
TCI (Tokyo Chemical Industry)	M2279	http://www.tcichemicals.com/eshop/en/us/commodity/M2279/index.html
THE BioTek	bt-274921	https://www.thebiotek.com/product/inhibitors/bt-274921
THE BioTek	bt-289487	https://www.thebiotek.com/product/others/bt-289487
eNovation Chemicals	D518319	https://www.enovationchem.com/ProductDetails.asp?ProductID=D518319

PubMed

Title	Date	PubMed
[Antibiotic therapy of cystic fibrosis in children].	2001	11544748
Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.	2001	11368281
[Antimicrobial activities of meropenem against clinically isolated strains in 1999].	2001 Apr	11436501
Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.	2001 Apr-Jun	11432485
Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood.	2001 Aug	11516936
Meropenem and continuous renal replacement.	2001 Aug	11505159
[The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem].	2001 Aug-Sep	11747791
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].	2001 Dec	11856982
Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999.	2001 Dec	11837636
Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.	2001 Dec	11810597
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.	2001 Dec	11793091
Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).	2001 Dec	11777658
MYSTIC program: summary of European data from 1997 to 2000.	2001 Dec	11777657
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).	2001 Dec	11777656
Determining the value of antimicrobial surveillance programs.	2001 Dec	11777655
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].	2001 Feb	11338681
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].	2001 Jul	11560055
Case report: recovery from persistent septicemic melioidosis.	2001 Jul	11504412
Occupational allergic contact dermatitis from meropenem.	2001 Jul	11422278
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.	2001 Jul	11418512
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.	2001 Jul	11418509
Use of broad spectrum antibiotics in six non-university Swiss hospitals.	2001 Jul 28	11582634
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.	2001 Jul 30	11485888
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). III. Secular changes in susceptibility].	2001 Jun	11525192
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.	2001 Jun	11450887
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.	2001 Jun	11442564
A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine.	2001 Jun	11438968
Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.	2001 Jun	11389117
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.	2001 Jun	11389111
Pharmacokinetics of meropenem in preterm neonates.	2001 Jun	11360025
Antifungal antibiotics and breakthrough bacteremias.	2001 Jun 1	11340523
Antibiotic selective pressure and development of bacterial resistance.	2001 May	11337221
In vitro activity of garlic oil and four diallyl sulphides against antibiotic-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.	2001 May	11328781
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs.	2001 May-Jun	11395191
Melioidosis: an emerging infection in Taiwan?	2001 May-Jun	11384520
[A case of eosinophilic pneumonia possibly due to ifenprodil].	2001 Nov	11855087
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].	2001 Nov	11828603
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!	2001 Nov	11750171
In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains.	2001 Nov	11679563
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.	2001 Sep	11714042
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.	2001 Sep 3	11527740
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase.	2001 Sep 7	11443136
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans.	2001 Sep-Oct	11561137
Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.	2002 Feb	11850170
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.	2002 Feb	11815589
Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains.	2002 Feb	11815587
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.	2002 Jan	11801485
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.	2002 Jan	11749761
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).	2002 Mar	11864948
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities.	2002 Mar 15	11850860

Patents

Sample Use Guides

In Vivo Use Guide

Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended. Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:02:32 UTC 2023` Edited by `admin` on `Wed Jul 05 23:02:32 UTC 2023`
Record UNII	YOP6PX0BAO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEROPENEM ANHYDROUS

Common Name

English

MEROPENEM [MI]

Common Name

English

MEROPENEM, ANHYDROUS

Common Name

English

meropenem [INN]

Common Name

English

(4R,5S,6S)-3-(((3S,5S)-5-(DIMETHYLCARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

Meropenem [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C260